MKTX · MarketAxess Holdings, Inc.

Current Thesis

MarketAxess’s thesis is completion of Intercontinental Exchange’s $167-per-share cash acquisition before a daily close below $155 invalidates the completion case. The September 11, 2026 adjusted market close was $163.00; the contractual consideration comes from the merger agreement announced July 30, 2026. This remains a binary acquisition story.

The September 4, 2026 preliminary proxy removes the earlier missing-document concern: it discloses an August 26 antitrust filing and expected September 25 waiting-period expiration. The shareholder meeting date remains blank. September 4 preliminary proxy

As an inference, the narrative is maturing — UBS’s July 31, Barclays’s August 10 and KBW’s August 11, 2026 price targets had already converged on $167. The September filing advances the process without changing the cash consideration. A revised agreement or termination would overturn that fixed-consideration framing.

Bullish and bearish views on MarketAxess Holdings, Inc.

The model's bull view on MarketAxess Holdings, Inc. (MKTX), in brief: Contractual consideration anchors the case. The bear view: Approval extends beyond US antitrust. The September 4, 2026 proxy also names required financial-regulatory approvals across the United States, Canada, the Netherlands, the United Kingdom and Singapore. Treating US antitrust as the sole remaining condition is unsupported.… Both cases follow in full.

Bull Case

• Contractual consideration anchors the case. The July 29, 2026 agreement specifies $167 per share in cash. Completion at those terms is the observable outcome supporting the thesis. ICE merger announcement filing
• Debt issuance supports financing capacity. Bloomberg’s August 12, 2026 report described ICE’s $3.75 billion bond sale priced August 11. That supports the financing case; issuance does not establish regulatory approval.
• Operating earnings remain documented. MarketAxess’s August 7, 2026 results reported second-quarter revenue of $218.4 million, net income of $68.3 million and an operating margin of 41.1%. Those figures establish operating profitability for that quarter, without establishing subsequent performance.

Bear Case

• Approval extends beyond US antitrust. The September 4, 2026 proxy also names required financial-regulatory approvals across the United States, Canada, the Netherlands, the United Kingdom and Singapore. Treating US antitrust as the sole remaining condition is unsupported. Preliminary proxy, regulatory approvals
• Standalone valuation remains a separate question. Morgan Stanley’s July 10, 2026 price target was $129 and Piper Sandler’s July 15 target was $128, according to the previously reported analyst actions. These historical opinions are neither current forecasts nor assured prices following termination.
• Ownership filings show substantial stakes. North Reef reported 9.55% on August 14, 2026, and AQR reported 5.59% on August 13 in Schedule 13G/A filings. Those disclosures establish ownership at the reported dates; they do not establish September exposure, hedges or investor intentions.

Setup & Price Structure

The supplied adjusted daily series records a September 11, 2026 close of $163.00, a three-month price increase of 35.5% and a 14-period relative strength index (RSI) of 72.8. Its 52-week high was $191.62, with the close 14.9% below that high. No moving-average value or trading-volume series is supplied, so neither moving-average support nor expanding participation is established.

The $155 research threshold published August 30, 2026 remains the daily-close invalidation condition. It is a defined thesis boundary, not a demonstrated moving-average level. Benzinga’s September 9, 2026 headline, “Top 3 Financial Stocks That May Crash This Quarter,” adds sentiment-oriented coverage; that isolated headline cannot establish retail crowding or predict a decline.

Catalyst Calendar (next 30 days)

• 2026-09-25 — Expected antitrust waiting-period expiration. The September 4 proxy specifies 11:59 p.m. Eastern Time under the Hart-Scott-Rodino Antitrust Improvements Act (HSR). Expiration without an extension or second request would resolve this procedural milestone, while other closing conditions remain. Preliminary proxy, regulatory approvals

The September 4, 2026 proxy still anticipates completion in the first half of 2027; it provides no exact closing date. September 25 is therefore a regulatory milestone, not a scheduled acquisition closing. Preliminary proxy, merger summary

What Would Change Our Mind

Failure of the completion structure would be recorded by a daily close below $155, retaining the research boundary published August 30, 2026. Such a close invalidates this price-defined thesis even if the agreement remains legally outstanding. A termination filing would independently defeat the acquisition premise; a disclosed second request would contradict an uncomplicated September 25 regulatory milestone without itself proving eventual failure.

Correlation Notes

This is a single-name acquisition setup. The July 29, 2026 agreement fixes cash consideration rather than an exchange ratio, so ICE’s share price does not mechanically determine the contractual payment. ICE merger filing No paired return series accompanies the September 11 market data; a numerical correlation with ICE, exchange operators or broader financial equities cannot be supported.